Nonoperative therapies for combined modality treatment of hepatocellular cancer: Expert consensus statement

HPB

Volumn 12, Issue 5, 2010, Pages 313-320

  Schwarz, Roderich E ^a   Abou Alfa, Ghassan K ^b   Geschwind, Jeffrey F ^c   Krishnan, Sunil ^d   Salem, Riad ^e   Venook, Alan P ^f  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^c JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^e NORTHWESTERN MEMORIAL HOSPITAL   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Chemoembolization; Chemotherapy; Consensus conference; Hepatocellular cancer; Hepatoma; Liver transplantation; Radiotherapy; Surgery

Indexed keywords

1 [4 (3 AMINO 1H INDAZOL 4 YL)PHENYL] 3 (2 FLUORO 5 METHYLPHENYL)UREA; BEVACIZUMAB; BRIVANIB; CISPLATIN; DOXORUBICIN; EPIRUBICIN; ERLOTINIB; FLOXURIDINE; IODINATED POPPYSEED OIL; MICROSPHERE; MITOMYCIN C; MITOXANTRONE; SORAFENIB; SUNITINIB; YTTRIUM 90;

ABDOMINAL PAIN; ABLATION THERAPY; ADVANCED CANCER; ASCITES; BILIRUBIN BLOOD LEVEL; CANCER CONTROL; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CHEMOEMBOLIZATION; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CONFERENCE PAPER; EXTERNAL BEAM RADIOTHERAPY; FEVER; GASTROINTESTINAL HEMORRHAGE; HUMAN; LIVER CELL CARCINOMA; LIVER TRANSPLANTATION; MULTIMODALITY CANCER THERAPY; PHOTON THERAPY; PORTAL VEIN; PORTAL VEIN THROMBOSIS; SIDE EFFECT; SYSTEMIC THERAPY; TREATMENT INDICATION; VOMITING;

EID: 77953570290     PISSN: 1365182X     EISSN: 14772574     Source Type: Journal    
DOI: 10.1111/j.1477-2574.2010.00183.x     Document Type: Conference Paper

References (75)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. (2009) Cancer statistics, 2009. CA Cancer J Clin 59:225-249.
2. Schwarz RE, Smith DD. (2008) Trends in local therapy for hepatocellular carcinoma and survival outcomes in the US population. Am J Surg 195:829-836.
3. Yamada R, Nakatsuka H, Nakamura K, Sato M, Itami M, Kobayashi N et al. (1980) Hepatic artery embolization in 32 patients with unresectable hepatoma. Osaka City Med J 26:81-96.
4. Yamada R, Sato M, Kawabata M, Nakatsuka H, Nakamura K, Takashima S. (1983) Hepatic artery embolization in 120 patients with unresectable hepatoma. Radiology 148:397-401.
5. Nakakuma K, Tashiro S, Hiraoka T, Uemura K, Konno T, Miyauchi Y et al. (1983) Studies on anticancer treatment with an oily anticancer drug injected into the ligated feeding hepatic artery for liver cancer. Cancer 52:2193-2200.
6. Konno T, Maeda H, Iwai K, Tashiro S, Maki S, Morinaga T et al. (1983) Effect of arterial administration of high-molecular-weight anticancer agent SMANCS with lipid lymphographic agent on hepatoma: a preliminary report. Eur J Cancer Clin Oncol 19:1053-1065.
7. Clouse ME, Perry L, Stuart K, Stokes KR. (1994) Hepatic arterial chemoembolization for metastatic neuroendocrine tumors. Digestion 55 (Suppl. 3):92-97.
8. Bruix J, Sala M, Llovet JM. (2004) Chemoembolization for hepatocellular carcinoma. Gastroenterology 127:S179-188.
9. Kawai S, Okamura J, Ogawa M, Ohashi Y, Tani M, Inoue J et al. (1992) Prospective and randomized clinical trial for the treatment of hepatocellular carcinoma-a comparison of lipiodol-transcatheter arterial embolization with and without adriamycin (first cooperative study). The Cooperative Study Group for Liver Cancer Treatment of Japan. Cancer Chemother Pharmacol 31 (Suppl.):S1-6.
10. Chang JM, Tzeng WS, Pan HB, Yang CF, Lai KH. (1994) Transcatheter arterial embolization with or without cisplatin treatment of hepatocellular carcinoma. A randomized controlled study. Cancer 74:2449-2453.
11. Geschwind JF, Ramsey DE, Cleffken B, van der Wal BC, Kobeiter H, Juluru K et al. (2003) Transcatheter arterial chemoembolization of liver tumors: effects of embolization protocol on injectable volume of chemotherapy and subsequent arterial patency. Cardiovasc Intervent Radiol 26:111-117.
12. Terayama N, Matsui O, Gabata T, Kobayashi S, Sanada J, Ueda K et al. (2001) Accumulation of iodized oil within the nonneoplastic liver adjacent to hepatocellular carcinoma via the drainage routes of the tumor after transcatheter arterial embolization. Cardiovasc Intervent Radiol 24:383-387.
13. Bhattacharya S, Novell JR, Winslet MC, Hobbs KE. (1994) Iodized oil in the treatment of hepatocellular carcinoma. Br J Surg 81:1563-1571.
14. Llovet JM, Real MI, Montana X, Planas R, Coll S, Aponte J et al. (2002) Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet 359:1734-1739.
15. Hepatocellulaire GdEedTdC. (1995) A comparison of lipiodol chemoembolization and conservative treatment for unresectable hepatocellular carcinoma. N Engl J Med 332:1256-1261.
16. Lo CM, Ngan H, Tso WK, Liu CL, Lam CM, Poon RT et al. (2002) Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology 35:1164-1171.
17. Aoki T, Imamura H, Hasegawa K, Matsukura A, Sano K, Sugawara Y et al. (2004) Sequential preoperative arterial and portal venous embolizations in patients with hepatocellular carcinoma. Arch Surg 139:766-774.
18. Llovet JM, Burroughs A, Bruix J. (2003) Hepatocellular carcinoma. Lancet 362:1907-1917.
19. Llovet JM. (2004) Treatment of Hepatocellular Carcinoma. Curr Treat Options Gastroenterol 7:431-441.
20. Takayasu K, Arii S, Ikai I, Omata M, Okita K, Ichida T et al. (2006) Prospective cohort study of transarterial chemoembolization for unresectable hepatocellular carcinoma in 8510 patients. Gastroenterology 131:461-469.
21. Livraghi T, Meloni F, Morabito A, Vettori C. (2004) Multimodal imageguided tailored therapy of early and intermediate hepatocellular carcinoma: long-term survival in the experience of a single radiologic referral center. Liver Transpl 10:S98-106.
22. Georgiades CS, Liapi E, Frangakis C, Park JU, Kim HW, Hong K et al. (2006) Prognostic accuracy of 12 liver staging systems in patients with unresectable hepatocellular carcinoma treated with transarterial chemoembolization. J Vasc Interv Radiol 17:1619-1624.
23. Bruix J, Llovet JM, Castells A, Montana X, Bru C, Ayuso MC et al. (1998) Transarterial embolization versus symptomatic treatment in patients with advanced hepatocellular carcinoma: results of a randomized, controlled trial in a single institution. Hepatology 27:1578-1583.
24. Hong K, Liapi E, Georgiades CS, Geschwind JF. (2005) Case-controlled comparison of a percutaneous collagen arteriotomy closure device versus manual compression after liver chemoembolization. J Vasc Interv Radiol 16:339-345.
25. Liapi E, Georgiades CC, Hong K, Geschwind JF. (2007) Transcatheter arterial chemoembolization: current technique and future promise. Tech Vasc Interv Radiol 10:2-11.
26. Liapi E, Geschwind JF. (2007) Transcatheter and ablative therapeutic approaches for solid malignancies. J Clin Oncol 25:978-986.
27. Liapi E, Lee KH, Georgiades CC, Hong K, Geschwind JF. (2007) Drugeluting particles for interventional pharmacology. Tech Vasc Interv Radiol 10:261-269.
28. Kamel IR, Liapi E, Reyes DK, Zahurak M, Bluemke DA, Geschwind JF. (2009) Unresectable hepatocellular carcinoma: serial early vascular and cellular changes after transarterial chemoembolization as detected with MR imaging. Radiology 250:466-473.
29. Georgiades CS, Hong K, D'Angelo M, Geschwind JF. (2005) Safety and efficacy of transarterial chemoembolization in patients with unresectable hepatocellular carcinoma and portal vein thrombosis. J Vasc Interv Radiol 16:1653-1659.
30. Sorafenib. http://www.fda.gov/AboutFDA/CentersOffices/CDER/ ucm129234.htm
31. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF et al. (2008) Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359:378-390.
32. Abou-Alfa GK, Schwartz L, Ricci S, Amadori D, Santoro A, Figer A et al. (2006) Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. J Clin Oncol 24:4293-4300.
33. Abou-Alfa GK, Zhao B, Capanu M, Guo P, Liu F, Jacobs G et al. (2008) Tumor necrosis as a correlate for response in subgroup of patients with advanced hepatocellular carcinoma (HCC) rreated with sorafenib. Ann Oncol (Abstract 547P) 19 (Suppl. 8):viii178.
34. Chan SL, Mo FK, Johnson PJ, Hui EP, Ma BB, Ho WM et al. (2009) New utility of an old marker: serial alpha-fetoprotein measurement in predicting radiologic response and survival of patients with hepatocellular carcinoma undergoing systemic chemotherapy. J Clin Oncol 27:446-452.
35. Abou-Alfa GK, Amadori D, Santoro A, Figer A, De Greve J, Lathia C et al. (2008) Is sorafenib safe and effective in patients with hepatocellular carcinoma and Child-Pugh B cirrhosis? J Clin Oncol 26:4518.
36. Furuse J, Ishii H, Nakachi K, Suzuki E, Shimizu S, Nakajima K. (2008) Phase I study of sorafenib in Japanese patients with hepatocellular carcinoma. Cancer Sci 99:159-165.
37. Miller AA, Murry DJ, Owzar K, Hollis DR, Kennedy EB, Abou-Alfa G et al. (2009) Phase I and pharmacokinetic study of sorafenib in patients with hepatic or renal dysfunction: CALGB 60301. J Clin Oncol 27:1800-1805.
38. Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S, Kim JS et al. (2009) Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, doubleblind, placebo-controlled trial. Lancet Oncol 10:25-34.
39. Giambartolomei S, Covone F, Levrero M, Balsano C. (2001) Sustained activation of the Raf/MEK/Erk pathway in response to EGF in stable cell lines expressing the Hepatitis C Virus (HCV) core protein. Oncogene 20:2606-2610.
40. Siegel AB, Cohen EI, Ocean A, Lehrer D, Goldenberg A, Knox JJ, et al. (2008) Phase II trial evaluating the clinical and biologic effects of bevacizumab in unresectable hepatocellular carcinoma. J Clin Oncol 26:2992-2998.
41. Zhu AX, Blaszkowsky LS, Ryan DP, Clark JW, Muzikansky A, Horgan K et al. (2006) Phase II study of gemcitabine and oxaliplatin in combination with bevacizumab in patients with advanced hepatocellular carcinoma. J Clin Oncol 24:1898-1903.
42. Sun W, Haller DG, Mykulowycz K, Rosen M, Soulen M, Capparo M et al. (2007) Combination of capecitabine, oxaliplatin with bevacizumab in treatment of advanced hepatocellular carcinoma (HCC): A phase II study. Journal of Clinical Oncology 25:4574.
43. Hsu C, Yang T, Hsu C, Toh H, Epstein RJ, Hsiao L et al. (2007) Modifieddose capecitabine + bevacizumab for the treatment of advanced/ metastatic hepatocellular carcinoma (HCC): A phase II, single-arm study. J Clin Oncol 25:15190.
44. Thomas MB, Morris JS, Chadha R, Iwasaki M, Kaur H, Lin E et al. (2009) Phase II trial of the combination of bevacizumab and erlotinib in patients who have advanced hepatocellular carcinoma. J Clin Oncol 27:843-850.
45. Zhu AX, Sahani DV, Duda DG, di Tomaso E, Ancukiewicz M, Catalano OA et al. (2009) Efficacy, safety, and potential biomarkers of sunitinib monotherapy in advanced hepatocellular carcinoma: a phase II study. J Clin Oncol 27:3027-3035.
46. Faivre S, Raymond E, Boucher E, Douillard J, Lim HY, Kim JS et al. (2009) Safety and efficacy of sunitinib in patients with advanced hepatocellular carcinoma: an open-label, multicentre, phase II study. Lancet Oncol 10:794-800.
47. Toh H, Chen P, Carr BI, Knox JJ, Gill S, Steinberg J et al. (2009) A phase II study of ABT-869 in hepatocellular carcinoma (HCC): Interim analysis. J Clin Oncol 27:4581.
48. Raoul JL, Finn RS, Kang YK, Park JW, Harris R, Coric V et al. (2009) An open-label phase II study of first- and second-line treatment with brivanib in patients with hepatocellular carcinoma (HCC). J Clin Oncol 27:4577.
49. Duran I, Hotte SJ, Hirte H, Chen EX, MacLean M, Turner S et al. (2007) Phase I targeted combination trial of sorafenib and erlotinib in patients with advanced solid tumors. Clin Cancer Res 13:4849-4857.
50. Chemoembolization with or without sorafenib tosylate in treating patients with liver cancer that cannot be removed by surgery. ECOG 1208. http://www.clinicaltrials.gov/ct2/show/NCT01004978?term=sorafenib+tace&rank= 11
51. Gupta S, Kobayashi S, Phongkitkarun S, Broemeling LD, Kan Z. (2006) Effect of transcatheter hepatic arterial embolization on angiogenesis in an animal model. Invest Radiol 41:516-521.
52. Mazzaferro V, Regalia E, Doci R, Andreola S, Pulvirenti A, Bozzetti F et al. (1996) Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 334:693-699.
53. Kulik LM, Atassi B, van Holsbeeck L, Souman T, Lewandowski RJ, Mulcahy MF et al. (2006) Yttrium-90 microspheres (TheraSphere) treatment of unresectable hepatocellular carcinoma: downstaging to resection, RFA and bridge to transplantation. J Surg Oncol 94:572-586.
54. Lewandowski RJ, Kulik LM, Riaz A, Senthilnathan S, Mulcahy MF, Ryu RK et al. (2009) A comparative analysis of transarterial downstaging for hepatocellular carcinoma: chemoembolization versus radioembolization. Am J Transplant 9:1920-1928.
55. Riaz A, Kulik L, Lewandowski RJ, Ryu RK, Giakoumis Spear G, Mulcahy MF et al. (2009) Radiologic-pathologic correlation of hepatocellular carcinoma treated with internal radiation using yttrium-90 microspheres. Hepatology 49:1185-1193.
56. Kulik LM, Carr BI, Mulcahy MF, Lewandowski RJ, Atassi B, Ryu RK et al. (2008) Safety and efficacy of 90Y radiotherapy for hepatocellular carcinoma with and without portal vein thrombosis. Hepatology 47:71-81.
57. Salem R, Lewandowski RJ, Mulcahy MF, Riaz A, Ryu RK, Ibrahim S et al. (2010) Radioembolization for hepatocellular carcinoma using Yttrium-90 microspheres: a comprehensive report of long-term outcomes. Gastroenterology 138:52-64.
58. Ten Haken RK, Martel MK, Kessler ML, Hazuka MB, Lawrence TS, Robertson JM et al. (1993) Use of Veff and iso-NTCP in the implementation of dose escalation protocols. Int J Radiat Oncol Biol Phys 27:689-695.
59. Krishnan S, Dawson LA, Seong J, Akine Y, Beddar S, Briere TM et al. (2008) Radiotherapy for hepatocellular carcinoma: an overview. Ann Surg Oncol 15:1015-1024.
60. Hawkins MA, Dawson LA. (2006) Radiation therapy for hepatocellular carcinoma: from palliation to cure. Cancer 106:1653-1663.
61. Ben-Josef E, Normolle D, Ensminger WD, Walker S, Tatro D, Ten Haken RK et al. (2005) Phase II trial of high-dose conformal radiation therapy with concurrent hepatic artery floxuridine for unresectable intrahepatic malignancies. J Clin Oncol 23:8739-8747.
62. Mornex F, Girard N, Beziat C, Kubas A, Khodri M, Trepo C et al. (2006) Feasibility and efficacy of high-dose three-dimensional-conformal radiotherapy in cirrhotic patients with small-size hepatocellular carcinoma non-eligible for curative therapies-mature results of the French Phase II RTF-1 trial. Int J Radiat Oncol Biol Phys 66:1152-1158.
63. Mendez Romero A, Wunderink W, Hussain SM, De Pooter JA, Heijmen BJ, Nowak PC et al. (2006) Stereotactic body radiation therapy for primary and metastatic liver tumors: A single institution phase i-ii study. Acta Oncol 45:831-837.
64. Dawson LA, Eccles C, Craig T. (2006) Individualized image guided iso- NTCP based liver cancer SBRT. Acta Oncol 45:856-864.
65. Chiba T, Tokuuye K, Matsuzaki Y, Sugahara S, Chuganji Y, Kagei K et al. (2005) Proton beam therapy for hepatocellular carcinoma: a retrospective review of 162 patients. Clin Cancer Res 11:3799-3805.
66. Bush DA, Hillebrand DJ, Slater JM, Slater JD. (2004) High-dose proton beam radiotherapy of hepatocellular carcinoma: preliminary results of a phase II trial. Gastroenterology 127:S189-193.
67. Kawashima M, Furuse J, Nishio T, Konishi M, Ishii H, Kinoshita T et al. (2005) Phase II study of radiotherapy employing proton beam for hepatocellular carcinoma. J Clin Oncol 23:1839-1846.
68. Sasaki Y, Imaoka S, Kasugai H, Fujita M, Kawamoto S, Ishiguro S, et al. (1987) A new approach to chemoembolization therapy for hepatoma using ethiodized oil, cisplatin, and gelatin sponge. Cancer 60:1194-1203.
69. Yu YQ, Xu DB, Zhou XD, Lu JZ, Tang ZY, Mack P. (1993) Experience with liver resection after hepatic arterial chemoembolization for hepatocellular carcinoma. Cancer 71:62-65.
70. Seong J, Keum KC, Han KH, Lee DY, Lee JT, Chon CY et al. (1999) Combined transcatheter arterial chemoembolization and local radiotherapy of unresectable hepatocellular carcinoma. Int J Radiat Oncol Biol Phys 43:393-397.
71. Seong J, Park HC, Han KH, Lee DY, Lee JT, Chon CY et al. (2000) Local radiotherapy for unresectable hepatocellular carcinoma patients who failed with transcatheter arterial chemoembolization. Int J Radiat Oncol Biol Phys 47:1331-1335.
72. Yasuda S, Ito H, Yoshikawa M, Shinozaki M, Goto N, Fujimoto H et al. (1999) Radiotherapy for large hepatocellular carcinoma combined with transcatheter arterial embolization and percutaneous ethanol injection therapy. Int J Oncol 15:467-473.
73. Guo WJ, Yu EX. (2000) Evaluation of combined therapy with chemoembolization and irradiation for large hepatocellular carcinoma. Br J Radiol 73:1091-1097.
74. Chia-Hsien Cheng J, Chuang VP, Cheng SH, Lin YM, Cheng TI, Yang PS et al. (2001) Unresectable hepatocellular carcinoma treated with radiotherapy and/or chemoembolization. Int J Cancer 96:243-252.
75. Han KH, Seong J, Kim JK, Ahn SH, Lee do Y, Chon CY. (2008) Pilot clinical trial of localized concurrent chemoradiation therapy for locally advanced hepatocellular carcinoma with portal vein thrombosis. Cancer 113:995-1003.